drugset / Trial / NCT00003693

Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

NCT00003693 ↗

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of dolastatin 10 in treating patients who have refractory or relapsed acute leukemia, chronic myelogenous leukemia in blast phase, or myelodysplastic syndrome.

Timeline

Start
1998-12-18
Primary completion
2001-10-30
Completion
2001-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject dolastatin 10 Peptide — Intravenous